Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Injuries | 18 | 2023 | 56 | 5.580 |
Why?
|
| Recovery of Function | 7 | 2017 | 88 | 1.630 |
Why?
|
| Tamoxifen | 3 | 2017 | 65 | 1.580 |
Why?
|
| Spinal Cord | 8 | 2014 | 94 | 1.540 |
Why?
|
| Neuroprotective Agents | 4 | 2017 | 245 | 1.420 |
Why?
|
| Locomotion | 5 | 2017 | 97 | 1.220 |
Why?
|
| Rats, Sprague-Dawley | 20 | 2023 | 1618 | 1.090 |
Why?
|
| Rats | 19 | 2023 | 3483 | 0.830 |
Why?
|
| Up-Regulation | 5 | 2006 | 513 | 0.720 |
Why?
|
| Motor Activity | 6 | 2014 | 418 | 0.630 |
Why?
|
| Estradiol | 2 | 2023 | 262 | 0.600 |
Why?
|
| Receptor, EphA4 | 2 | 2007 | 5 | 0.580 |
Why?
|
| Neuroglia | 1 | 2017 | 124 | 0.570 |
Why?
|
| Gliosis | 2 | 2017 | 24 | 0.550 |
Why?
|
| RNA, Messenger | 8 | 2011 | 1207 | 0.540 |
Why?
|
| Animals | 20 | 2023 | 15081 | 0.480 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2017 | 70 | 0.460 |
Why?
|
| Ligands | 3 | 2011 | 349 | 0.430 |
Why?
|
| Nerve Regeneration | 3 | 2009 | 40 | 0.430 |
Why?
|
| Neurons | 2 | 2017 | 1175 | 0.420 |
Why?
|
| Evoked Potentials, Motor | 3 | 2011 | 10 | 0.410 |
Why?
|
| Suramin | 1 | 2011 | 4 | 0.400 |
Why?
|
| Ephrin-A1 | 1 | 2011 | 1 | 0.400 |
Why?
|
| Pyridoxal Phosphate | 1 | 2011 | 11 | 0.400 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 29 | 0.390 |
Why?
|
| Female | 18 | 2017 | 20969 | 0.370 |
Why?
|
| Antioxidants | 1 | 2014 | 416 | 0.370 |
Why?
|
| Pain, Intractable | 1 | 2009 | 2 | 0.360 |
Why?
|
| Receptor, EphB3 | 2 | 2006 | 2 | 0.350 |
Why?
|
| Buprenorphine | 1 | 2009 | 21 | 0.340 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 1015 | 0.340 |
Why?
|
| Membrane Proteins | 1 | 2012 | 517 | 0.320 |
Why?
|
| Caveolin 1 | 2 | 2019 | 29 | 0.310 |
Why?
|
| Receptors, Eph Family | 2 | 2011 | 4 | 0.310 |
Why?
|
| Analgesics, Opioid | 1 | 2009 | 197 | 0.300 |
Why?
|
| Receptor, EphA7 | 1 | 2006 | 1 | 0.290 |
Why?
|
| Astrocytes | 4 | 2012 | 255 | 0.280 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 26 | 0.260 |
Why?
|
| Estrogen Receptor alpha | 2 | 2017 | 111 | 0.260 |
Why?
|
| Gene Expression | 3 | 2012 | 674 | 0.250 |
Why?
|
| Docosahexaenoic Acids | 2 | 2016 | 18 | 0.240 |
Why?
|
| Pain | 1 | 2006 | 251 | 0.230 |
Why?
|
| Brain | 2 | 2012 | 1346 | 0.230 |
Why?
|
| Apoptosis | 2 | 2009 | 1398 | 0.220 |
Why?
|
| Behavior, Animal | 2 | 2017 | 314 | 0.210 |
Why?
|
| Astrocytoma | 2 | 2019 | 14 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 360 | 0.190 |
Why?
|
| Time Factors | 3 | 2014 | 1742 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 893 | 0.190 |
Why?
|
| Signal Transduction | 3 | 2019 | 1908 | 0.180 |
Why?
|
| Stress, Mechanical | 1 | 2019 | 113 | 0.170 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 626 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2011 | 859 | 0.140 |
Why?
|
| Phosphopyruvate Hydratase | 2 | 2006 | 33 | 0.140 |
Why?
|
| Caveolae | 1 | 2016 | 9 | 0.140 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2016 | 22 | 0.130 |
Why?
|
| Eye Proteins | 1 | 2016 | 46 | 0.130 |
Why?
|
| Sex Characteristics | 1 | 2017 | 230 | 0.130 |
Why?
|
| Myelin Sheath | 2 | 2012 | 48 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 623 | 0.130 |
Why?
|
| Drug Implants | 1 | 2014 | 21 | 0.120 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 15 | 0.120 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2014 | 19 | 0.120 |
Why?
|
| Estrogen Antagonists | 1 | 2014 | 28 | 0.120 |
Why?
|
| Neural Conduction | 2 | 2011 | 17 | 0.110 |
Why?
|
| Thoracic Vertebrae | 2 | 2010 | 7 | 0.110 |
Why?
|
| Ion Channels | 1 | 2012 | 71 | 0.110 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 47 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2009 | 1371 | 0.100 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2011 | 13 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 461 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 131 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2011 | 133 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2011 | 62 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 189 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2011 | 444 | 0.090 |
Why?
|
| Cocaine | 1 | 2012 | 232 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2010 | 207 | 0.090 |
Why?
|
| Second Messenger Systems | 1 | 2009 | 14 | 0.090 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2009 | 11 | 0.090 |
Why?
|
| Nociceptors | 1 | 2009 | 32 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 306 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2014 | 938 | 0.080 |
Why?
|
| Protein Isoforms | 2 | 2012 | 130 | 0.080 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2006 | 17 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 39 | 0.070 |
Why?
|
| Hyperalgesia | 1 | 2006 | 18 | 0.070 |
Why?
|
| Axons | 1 | 2007 | 108 | 0.070 |
Why?
|
| Patch-Clamp Techniques | 1 | 2006 | 223 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2006 | 223 | 0.070 |
Why?
|
| Anterior Horn Cells | 1 | 2005 | 5 | 0.070 |
Why?
|
| Growth Cones | 1 | 2005 | 12 | 0.070 |
Why?
|
| Growth Inhibitors | 1 | 2005 | 26 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2006 | 171 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 136 | 0.070 |
Why?
|
| Optic Nerve Injuries | 1 | 2005 | 18 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2009 | 1369 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 550 | 0.060 |
Why?
|
| Neural Pathways | 1 | 2005 | 124 | 0.060 |
Why?
|
| Cell Communication | 1 | 2005 | 97 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 803 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2005 | 121 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2006 | 484 | 0.060 |
Why?
|
| Ephrins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Male | 2 | 2017 | 20025 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2019 | 30 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 502 | 0.040 |
Why?
|
| Cell Survival | 1 | 2019 | 864 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 176 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 218 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 196 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 243 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 269 | 0.030 |
Why?
|
| Calcium | 1 | 2016 | 480 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 928 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 972 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 20 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 62 | 0.030 |
Why?
|
| Hindlimb | 1 | 2011 | 27 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 54 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2011 | 56 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 267 | 0.020 |
Why?
|
| Microglia | 1 | 2011 | 166 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 618 | 0.020 |
Why?
|
| Humans | 2 | 2019 | 37093 | 0.010 |
Why?
|
| Rhombencephalon | 1 | 2003 | 8 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 129 | 0.010 |
Why?
|